

Learner Notification

MED Learning Group

Development of Novel Therapies for the Treatment of Patients with Uterine Fibroids: What are the Data Telling Us?

August 21, 2023 – August 21, 2024

Online

Acknowledgement of Financial Commercial Support

Pfizer

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Explain the need for novel therapeutic approaches to the management of UFs based on the challenges associated with standard of care medical therapies.
2. Describe results from clinical trials assessing the efficacy and safety of newly-approved and emerging combination therapies that include GnRH antagonists for the long-term management of UFs.
3. Evaluate the contributions of new clinical guidance and shared decision-making approaches to the development of management plans for patients with UFs.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Laura	Aibara	NA
Russie	Allen	NA
Surabhi	Dangi-Garimella	NA
Matthew	Frese	NA
Christina	Gallo	NA
Nicole	Longo	NA
Andrea S.	Lukes	Myovant: Speakers' Bureau, AbbVie, Bayer Healthcare Pharmaceuticals, Merck & Co., Mylan, Myovant, Organon: Contracted Research
Jessica	McMullen	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com